<DOC>
	<DOC>NCT01238367</DOC>
	<brief_summary>This trial is conducted in Japan. The aim of this clinical trial is to investigate the pharmacokinetics (the effect of the investigated drug on the body) and safety of turoctocog alfa (recombinant factor VIII (N8)) in Japanese subjects with haemophilia A.</brief_summary>
	<brief_title>A Single Dose Trial of Recombinant Factor VIII (N8) in Japanese Subjects With Haemophilia A: An Extension to Trial NN7008-3543</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Blood Coagulation Disorders</mesh_term>
	<mesh_term>Hemostatic Disorders</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Japanese subjects who have completed NN70083543 No detectable inhibitors to factor VIII Congenital or acquired coagulation disorders other than haemophilia A Planned surgery during the trial period Receipt of any investigational drug other than recombinant factor VIII (N8) within 30 days of trial product administration</criteria>
	<gender>Male</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>66 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>